作者
Bella Ungar, Tal Engel, Doron Yablecovitch, Adi Lahat, Alon Lang, Benjamin Avidan, Ofir Har-Noy, Dan Carter, Nina Levhar, Limor Selinger, Sandra Neuman, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Uri Kopylov, Yehuda Chowers, Timna Naftali, Efrat Broide, Eyal Shachar, Rami Eliakim, Shomron Ben-Horin
发表日期
2018/6/1
期刊
Official journal of the American College of Gastroenterology| ACG
卷号
113
期号
6
页码范围
890-898
出版商
LWW
简介
OBJECTIVES:
Adalimumab is usually self-injected at home, making prospective serial-sampling studies challenging and scarce. This has led to a gap in knowledge about evolution of anti-adalimumab antibodies (AAAs) over time and its correlation with clinical and inflammatory outcomes.
METHODS:
A program for home visits by physicians at induction, every 3 months and at event of relapse, was established prospectively for Crohn's disease (CD) patients. At each visit, patients’ clinical scores were determined and sera were obtained for C-reactive protein, drug, and AAA levels. This cohort was compared to a parallel prospective cohort of infliximab-treated CD patients. In a subgroup of 29 patients, trough and in-between-trough levels were compared, to elucidate the importance of timing of sampling during the injection cycle.
RESULTS:
Ninety-eight CD patients starting adalimumab were prospectively followed …
学术搜索中的文章
B Ungar, T Engel, D Yablecovitch, A Lahat, A Lang… - Official journal of the American College of …, 2018